Clinical Trial Update: SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated [Phase 2]

View source ↗

Summary

This document reports the termination of a Phase 2 trial of SU5416 (semaxanib) in patients with previously treated metastatic melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• SU5416 (semaxanib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Melanoma, Stage IV Melanoma | Phase 2 | Status: TERMINATED